ARTES Biotechnology and Bio Farma Announce Collaboration in Vaccine Development

16-Jul-2013 - Germany

ARTES and Bio Farma announced to join forces for the development and manufacturing of vaccine candidates. The agreed collaboration involved the strength of both partners. Under this commitment a first agreement for VLP based vaccine technology transfer was signed on July 1st in Bandung, Indonesia.

“We are extremely delighted about the mutually agreed collaboration. Bio Farma is a strong and reliable pharmaceutical partner and the only vaccine and antisera producer for humans in Indonesia. We are more than confident, that we along with Bio Farma will develop vaccines highly relevant for the Indonesian and neighboring markets. We expect that especially developments based on our Metavax® technology will contribute to Bio Farma´s vaccine portfolio”, Dr. Michael Piontek, founder and managing director of ARTES Biotechnology.

Metavax® is a patent protected VLP technology, based on modifications to duck hepatitis B virus. The approach elicits a highly potent immune response and therefore a broader protection than the currently available VLP approaches. ARTES´ Metavax® platform is suitable for the development and production of safe and cost-effective vaccines.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance